A specific lot of Xanax XR is off the market after the manufacturer found the tablets failed a key quality test, raising concerns that patients may not be getting the full effect of their medication.
Viatris, Inc. voluntarily recalled the lot on March 17, according to an FDA Enforcement Report. The affected product is a 3-milligram extended-release alprazolam tablet, packaged in 60-tablet bottles, produced in Ireland and distributed by Viatris Specialty LLC in Morgantown, West Virginia. The lot number is 8177156, with an expiration date of February 28, 2027.
The problem is a failed dissolution test. Dissolution testing measures how quickly and completely a tablet's active ingredient breaks down and becomes available to the body. For extended-release formulations like Xanax XR, which are designed to deliver medication gradually over several hours, meeting those specifications is critical to consistent symptom control.
Aleksey Aronov, a board-certified adult geriatric primary care nurse practitioner and founder of VIPs IV, told Healthline that the failure does not mean the drug is dangerous. "It is just a quality control issue that may result in the patient not benefiting from the medicine when they take it," he said. "Pills that fail to dissolve essentially may not be effective."
In practical terms, a patient taking tablets from this lot could experience inadequate relief from anxiety or panic symptoms without knowing why. The medication simply may not be releasing alprazolam at the rate or level the body needs.
Aronov and other experts urge patients who have the recalled lot to contact their doctor about getting a replacement prescription. But they are equally clear on one point: do not stop taking the medication abruptly. Xanax is a benzodiazepine, a drug class that requires gradual tapering under medical supervision. Stopping suddenly can trigger withdrawal symptoms that may be more serious than the original anxiety being treated.
Patients can verify whether their bottle is part of the recall by checking the lot number printed on the label. Anyone with questions can contact Viatris directly or speak with their pharmacist or prescribing physician. The FDA's classification of the recall indicates the product is unlikely to cause serious health consequences, but the agency and the company are still urging affected patients to act.
